Serving To Educate Primary Care Clinicians On Metabolic Issues

Evidence Based Medicine Header 1

Medical Education Header 2

Metabolic Diseases Header 4

Survey

ADA Anemia in CKD Three

I am a(n)…

[ Required ]

Select...

How many years have you been in practice?

[ Required ]

Select...

What is your practice setting?

[ Required ]

Select...

Number of patients seen per month with chronic kidney disease

[ Required ]

Select...

Please rate the following:

Degree to which your educational expectations were met

[ Required ]

Select...

Relevance to your practice

[ Required ]

Select...

Effective faculty presenter

[ Required ]

Select...

Overall Presentation

[ Required ]

Select...

Describe evidence for emerging agents being studied in clinical trials for anemia in CKD.

[ Required ]

Select...

Agree or Disagree?

The presentation was fair and balanced, free of commercial bias.

[ Required ]

Select...

I feel more competent as a result of the presentation.

[ Required ]

Select...

The presentation was scientifically rigorous.

[ Required ]

Select...

The content contributed valuable information that will assist in improving patient outcomes

[ Required ]

Select...

Will you change your practice behaviors as a result of the presentation?

[ Required ]

Select...

What will you change?

[ Required ]

If Other

What barriers to change do you foresee?

[ Required ]

If Other

What was your level of knowledge on this subject?

Before the presentation

[ Required ]

Select...

After the presentation

[ Required ]

Select...

True or False? HIF-PH inhibitors improve the utilization of iron.

[ Required ]

Which of the following is unique to the investigational class of agents, hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) compared to erythropoiesis-stimulating agents (ESAs) for anemia in CKD?

[ Required ]

How confident do you feel in your answer to the previous question?

[ Required ]

Select...